Management of Diaper-Type Rash in Patients Taking SGLT2 Inhibitors
Treat the genital rash with topical antifungal therapy (such as clotrimazole or miconazole) and optimize genital hygiene practices, while continuing the SGLT2 inhibitor in most cases, as these genital mycotic infections are typically mild and do not require medication discontinuation.
Understanding the Problem
SGLT2 inhibitors increase urinary glucose excretion, creating a glucose-rich environment in the genital area that predisposes patients to fungal infections. Genital mycotic infections (GMIs) are the most common adverse effect of SGLT2 inhibitors, occurring in 10-15% of women and less frequently in men, with uncircumcised males at higher risk than circumcised males 1, 2.
Initial Management Approach
First-Line Treatment
- Apply topical antifungal agents (clotrimazole, miconazole, or similar) to the affected area 3, 4
- These infections are typically mild and responsive to standard antifungal treatment 2, 4
- Most cases resolve without requiring SGLT2 inhibitor discontinuation 2
Hygiene Optimization
- Counsel patients on meticulous genital hygiene practices to reduce infection risk 1, 3, 4
- Keep the area clean and dry
- Change undergarments frequently if moisture is present
- Consider barrier emollients to protect skin 5
When to Consider Oral Antifungals
If topical therapy fails or infection is severe:
- Oral antifungal agents can be used but require careful attention to QTc prolongation, especially in patients taking antiarrhythmic drugs or other QTc-prolonging medications 3
- Monitor ECG if using oral antifungals in at-risk patients
Decision to Continue vs. Discontinue SGLT2 Inhibitor
Continue the SGLT2 inhibitor if:
- First episode of GMI
- Mild to moderate infection
- Patient has cardiovascular disease, heart failure, or chronic kidney disease where SGLT2 inhibitor provides mortality/morbidity benefit 3, 1, 6
- Infection responds to antifungal treatment
Consider discontinuation only if:
- Severe, recurrent GMIs despite treatment and hygiene measures 3, 4
- Patient has history of multiple previous GMIs before starting SGLT2 inhibitor 3
- Female patients with particularly severe, recurrent infections unresponsive to treatment 4
Critical Caveat
The cardiovascular and renal benefits of SGLT2 inhibitors (reduced mortality, heart failure hospitalization, and kidney disease progression) often outweigh the inconvenience of manageable GMIs 7, 1, 2. Discontinuing an SGLT2 inhibitor solely for a mild, treatable GMI may expose the patient to greater morbidity and mortality risk from their underlying cardiovascular or renal disease.
Prevention for Future Episodes
- Optimize diabetes control to reduce glucose levels and subsequent glucosuria 4
- Reinforce genital hygiene education 1, 4
- Consider prophylactic antifungal therapy if recurrent infections occur despite optimal hygiene
- In uncircumcised males, emphasize proper hygiene practices 2
Risk Stratification for Recurrence
Highest risk patients (consider more aggressive prevention):
- Women (10-15% baseline risk) 1, 2
- History of previous GMIs before SGLT2 inhibitor 3, 4
- Uncircumcised males 2, 4
- Poor glycemic control
Lowest risk patients:
- Circumcised males 4
- No prior history of GMIs
- Well-controlled diabetes